In EGFR Activating Mutations Osimertinib is Now The Standard of Care - 102262

Spotlight
Video

In EGFR Activating Mutations Osimertinib is Now The Standard of Care

Loading........
Description: Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how in EGFR Activating Mutations Osimertinib is Now The Standard of Care from the 22nd Annual Perspectives in Thoracic Oncology in New York http://imedex.com/perspecti...
Shared By : thoraciconcology
Posted on : 12/27/17
Added : 25 days ago



Recommended

Nothing found.

More From thoraciconcology

Nothing found.